Curis price target lowered to $16 from $20 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Curis (CRIS) to $16 from $20 due to dilution from the recently announced deal, while keeping a Buy rating on the shares after the company provided an update from the ongoing TakeAim Lymphoma trial for emavusertib combined with Imbruvica in patients with r/r primary CNS lymphoma. The company stated that it has had successful meetings with the FDA and EMA on the suitability of using the TakeAim Lymphoma study to support a potential accelerated approval path in pCNSL.